Plain-language summary

This Phase 3 trial is comparing Golidocitinib, Chidamide, and other medications against other options for people whose T-cell lymphoma has come back or has not responded to previous treatment. Patients are randomly assigned to different treatment groups to see which approach works best. This trial does not currently list US sites.

Who can join (key eligibility)

• Age 18 Years or older
• Lymphoma came back or did not respond to prior treatment
• Must be well enough for treatment (adequate performance status)

Final eligibility is determined by the trial team. This list is a starting point only.

What's being tested

Golidocitinib (DRUG): 150 mg, orally, once daily, with or without food, in a 21-day cycle | Chidamide (DRUG): 30 mg, orally, twice a week, with an interval of no less than 3 days in a 21-day cycle | Gemcitabine (DRUG): 1000 mg/m2, intravenous infusion, administered on Day 1, Day 8 and Day 15 of a 28-day cycle

Drugs / treatments

Golidocitinib, Chidamide, Gemcitabine

Treatment length

Ask the trial team for details

Visit frequency

Ask the trial team for details